Amplia Therapeutics (ASX:ATX) received formal approval from the US Patent and Trademark Office for a patent covering a salt and crystal form of its cancer drug candidate, narmafotinib, being developed clinically, according to a Wednesday Australian bourse filing.
The patent, allowed in September, has been granted in major markets such as Europe, Japan, India, Korea, and Australia, securing narmafotinib's protection until at least 2040, with other regions still under review, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.